← Leaderboards
Sangeetha Meda Reddy
Ut Southwestern Medical Center
$987,512
Attributed
$987,512
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $246.9K · FY2022–25$250K$187.5K$125K$62.5K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$987,512 · 1
By mechanism
K08$987,512 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Janna M Journeycake$540,000
- Chuo Chen$9,073,859
- Deepak Nijhawan$7,364,715
- Ignacio I. Wistuba$32,209,830
- Allison Dunn$408,639
Others in their field
Other Rising Stars on “Clinical Trials Design”
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Sabrina Paganoni · Massachusetts General Hospital$30,895,527
- Suma Babu · Massachusetts General Hospital$30,895,527
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jennifer Lee O'Brien · University Of South Florida$15,110,862
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
Research focus
Clinical Trials DesignCorrelative StudyAdvisory CommitteesClinical TrialsAgonistAntigensAntigen TargetingAnthracyclineBioinformaticsAdaptive ImmunityAntigen-Presenting CellsB-LymphocytesBreastBreast Cancer PatientCancer SubtypesCancer TherapyCd8-Positive T-LymphocytesCellsCell TypeChemotherapyAntigen PresentationClinical EfficacyClinical InvestigationDefect
Grant awards (4)
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy$246,878
K08 · FY2025 · CA · contact PI
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy$246,878
K08 · FY2024 · CA · contact PI
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy$246,878
K08 · FY2023 · CA · contact PI
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy$246,878
K08 · FY2022 · CA · contact PI